4971 results for "Psychedelics"
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Journal of Psychopharmacology – January 18, 2017
Summary
Nearly 40% of individuals achieved continuous smoking cessation after a single psychedelic experience, suggesting a novel approach in clinical psychology. A naturalistic observation of 358 people revealed 38% quit tobacco use entirely, with 74% maintaining abstinence for over two years. Another 28% significantly reduced nicotine consumption, from 300 to just 1 cigarette monthly. These findings indicate psychedelics may aid smoking cessation by altering life priorities and improving emotional regulation, representing a promising avenue in medicine and psychiatry for addiction treatment.
Abstract
Data suggest psychedelics such as psilocybin and lysergic acid diethylamide (LSD) may hold therapeutic potential in the treatment of addictions, in...
Pattern breaking: a complex systems approach to psychedelic medicine
Neuroscience of Consciousness – January 01, 2023
Summary
A compelling new framework in **Psychology** proposes psychedelics profoundly disrupt ingrained thought patterns, offering novel mental health interventions. Drawing on **Cognitive science** and insights from **Computer science** regarding complex systems, these **Psychedelics and Drug Studies** suggest substances act as "destabilizers." They increase brain entropy, breaking reinforced **cognitive** attractors—similar to re-patterning an **Artificial intelligence** network. This neurophysiological shift, detectable through advanced **Biochemical Analysis and Sensing Techniques**, allows for new conceptualizations in psychotherapy, optimizing treatment and mitigating risks during the experience and recovery.
Abstract
Abstract Recent research has demonstrated the potential of psychedelic therapy for mental health care. However, the psychological experience underl...
Turn on, Tune in, and Drop out: Predictors of Attrition in a Prospective Observational Cohort Study on Psychedelic Use
Journal of Medical Internet Research – May 04, 2021
Summary
Personality traits significantly predict attrition in web-based Psychedelics and Drug Studies, a critical area for Health psychology. Among 654 participants, individuals lower in conscientiousness (β=–0.079) or higher in extraversion (β=0.082) were more likely to drop out. This insight, derived from logistic regression models, suggests potential selection bias in Clinical psychology research. Crucially, neither challenging psychedelic experiences nor initial enthusiasm predicted attrition. Understanding these Big Five personality traits informs how Psychology interprets findings, ensuring more robust conclusions from studies exploring complex human experiences.
Abstract
Background The resurgence of research and public interest in the positive psychological effects of psychedelics, together with advancements in digi...
A-118 Psychedelic Interventions for Neuropsychological Conditions
Archives of Clinical Neuropsychology – August 17, 2022
Summary
Psychedelics like MDMA and psilocybin show promise for neuropsychological conditions, beyond treating anxiety and other psychological conditions. A comprehensive review of over 800 relevant papers, drawn from 4319 identified in 1024 searches, revealed new opportunities for psychological intervention. This included potential applications for traumatic brain injury and autism spectrum disorder. While these psychedelic therapies are advancing through clinical trials in psychiatry and medicine, some contraindications exist for specific co-occurring psychological disorders, highlighting the evolving landscape of drug studies and their impact on clinical psychology.
Abstract
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depres...
Adapting psychedelic medicine for headache and chronic pain disorders.
Expert review of neurotherapeutics – January 01, 2023
Summary
Psychedelics like psilocybin and lysergic acid diethylamide show promising potential in treating stubborn headache disorders and chronic pain conditions. Beyond their known benefits for depression, these compounds may offer relief through different mechanisms than traditional painkillers. Early clinical trials and patient reports suggest psychedelics could provide lasting pain reduction with fewer side effects than current treatments.
Abstract
While the majority of current research and development surrounds depression, demoralization, and substance use disorders, there are numerous report...
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports – October 24, 2023
Summary
Psychedelics, powerful hallucinogens like psilocybin, Lysergic acid diethylamide, and mescaline, are re-emerging in medicine for psychiatry, improving mood and psychological well-being. Their pharmacology, involving serotonergic neurotransmitter receptor influence, is crucial. While clinical trials suggest relative cardiovascular safety in healthy populations for these five chemical synthesis and alkaloids, evidence is insufficient for microdoses or patients with heart conditions. Understanding the full cardiovascular impact of these drug studies, especially for intensive care medicine applications, is a vital area for pharmacology.
Abstract
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychi...
A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
Journal of Humanistic Psychology – September 16, 2021
Summary
As psychedelic therapies near approval, underground psychotherapists navigate complex ethical challenges using MDMA and psilocybin. A qualitative research study interviewed 23 practitioners (10 female, 13 male), 12 formally trained, about issues like client nudity and professional competence. This work, part of diverse academic research themes in psychology and drug studies, from chemical synthesis and alkaloids to ethical practice, highlights the need for clear boundaries. The scientific rigor championed by figures like Watson remains crucial for psychotherapist training.
Abstract
As both 3,4-methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted psychedelic psychotherapy near U.S. Food and Drug Administration (FDA) ap...
Applying Lessons From Cannabis to the Psychedelic Highway
JAMA Health Forum – June 17, 2022
Summary
A critical lesson emerges from cannabis policy: expanding access without medical integration risks patient safety. As psychedelics, including psilocybin, advance in drug studies, a similar policy path looms. Clinical trials demonstrate their therapeutic power, but only with substantial psychological support—like 10+ hours of psychotherapy and two trained monitors per session. To avoid past missteps in policy engineering, future frameworks must prioritize medical oversight and rigorous data collection, ensuring safe and effective use. This approach is vital for public health.
Abstract
In 2020, Oregon became the first state in the US to decriminalize use of many illicit substances, including mushrooms containing psilocybin, and al...
Human behavioral pharmacology of psychedelics.
Advances in pharmacology (San Diego, Calif.) – January 01, 2022
Summary
No Summary
Abstract
The past decade has witnessed a rapid growth of research on the basic science and clinical understanding of psychedelics. This chapter provides an ...
The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis.
Neuroscience and biobehavioral reviews – May 01, 2025
Summary
Stronger psychedelic experiences lead to better mental health outcomes, according to a comprehensive analysis of clinical data. Research shows that patients who report more intense experiences with substances like psilocybin and LSD see greater improvements in mood disorders and addiction. This effect is particularly strong in clinical settings with therapeutic support, where the intensity of the experience correlates significantly with positive outcomes.
Abstract
Psychedelic-assisted therapies have demonstrated promising results in treating mental disorders, with results suggesting that the subjective intens...
Psychedelics, epilepsy, and seizures: a review
Frontiers in Pharmacology – January 12, 2024
Summary
Psychedelics are proving clinically efficacious for various neurological and psychiatric disorders, yet all clinical trials exclude individuals with epilepsy or a history of seizures. This significant population, often overlooked in drug studies, faces exclusion without evidence that these compounds, many being alkaloids, induce seizures. Analysis of several cases suggests these substances, influencing behavior via neurotransmitter receptors, are safe in controlled clinical settings, even promoting seizure remission for some. This challenges current medicine, suggesting a broader role for psychedelic therapy.
Abstract
Psychedelic compounds have been utilized by humans for centuries for medicinal, religious, and tribal purposes. Clinical trial data starting from t...
Psychedelic Treatments for Substance Use Disorder and Substance Misuse: A Mixed Methods Systematic Review
Journal of Psychoactive Drugs – March 18, 2023
Summary
Promising insights emerge for psychedelic medicine in psychiatry. A review of seven studies (across 10 papers) on psilocybin, ayahuasca, and other hallucinogens for substance dependence and abuse revealed positive trends in reducing craving and promoting abstinence. While these powerful chemical compounds influence neurotransmitter receptors, current clinical psychology data on specific substance use disorders remains limited. Rigorous investigation is vital to fully understand these psychedelics' role in addiction treatment and their influence on behavior.
Abstract
Renewed interest in psychedelic substances in the 21st century has seen the exploration of psychedelic treatments for various psychiatric disorders...
Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research
Frontiers in Psychiatry – November 12, 2021
Summary
Individuals with chronic pain who self-medicate with psychedelics report substantial pain score improvements. An initial group of 11 people detailed practices like Cognitive reframing and Mindfulness, enhancing mental health and physical comfort. This preliminary work, relevant to Psychiatry, Clinical psychology, and broader Psychology, suggests psychedelics, often explored in Drug Studies for their Chemical synthesis and alkaloids, offer a promising Complementary and Alternative Medicine approach for this population. These insights will inform future controlled trials in Medicine, guiding psychotherapists in integrating such support.
Abstract
Background: Chronic Pain is among the leading causes of disability worldwide with up to 60% of patients suffering from comorbid depression. Psyched...
Three Cases of Depersonalization/Derealization Disorder Related to the Use of Classic Psychedelics
SUCHT - Zeitschrift für Wissenschaft und Praxis / Journal of Addiction Research and Practice – December 01, 2025
Summary
Depersonalization-derealization disorder (DDD) can follow psychedelic use, affecting individuals for months. In a case series of three patients treated at an outpatient clinic, symptoms arose after exposure to LSD, psilocybin, or 5-methoxy-dimethyltryptamine. Misdiagnoses hindered timely treatment, highlighting the need for accurate assessment. Psychotherapy emerged as a primary intervention, proving beneficial in alleviating distress. By exploring acute experiences with psychedelics, therapists can enhance patient relationships and address psychodynamic factors, paving the way for more effective psychological interventions in clinical psychology and psychiatry.
Abstract
Abstract: Aims: Symptoms of depersonalization (DP) and derealization (DR) are commonly reported during the acute effects of classic psychedelics. I...
Harnessing psychedelics for treating posttraumatic stress disorder: Does the science support all the hype?
Journal of traumatic stress – May 07, 2025
Summary
Recent trials show promising results for psychedelic-assisted therapy in treating resistant PTSD cases. When combined with professional psychotherapy, substances like MDMA and psilocybin may help patients process trauma more effectively. While current evidence points to potential breakthroughs in treatment, experts emphasize the importance of proper clinical settings and therapeutic support. Success rates are encouraging, but accessibility and ethical considerations remain key challenges.
Abstract
This paper is an edited transcript of a plenary panel held at the 2024 Annual Meeting of the International Society for Traumatic Stress Studies (IS...
High time? Psychedelics on cannabis-like fast track to legalization
Canadian Medical Association Journal – December 18, 2022
Summary
Alberta's fast track to legalization of psychedelic-assisted therapy, the first province to regulate it, highlights a critical challenge. Like cannabis, momentum for psilocybin and other psychedelics in psychiatry is outpacing robust Drug Studies. While promising, only an estimated 12% of conditions currently have extensive evidence from Cannabis and Cannabinoid Research or similar fields. Ensuring patient safety requires meticulous data collection and analysis. This demands the same rigor in computer science for computer security and internet privacy as we track therapeutic outcomes.
Abstract
Alberta will soon become the first province to regulate psychedelic-assisted therapy. But, as with cannabis, momentum for medical access to psyched...
Beyond the numbers: reimagining healing with psychedelics for eating disorders.
Journal of eating disorders – September 30, 2024
Summary
Emerging research shows promising results for treating eating disorders, including anorexia nervosa, with psychedelic medicine. Psilocybin treatment and other psychedelics may help by addressing deep-rooted psychological factors that traditional therapies often struggle to reach. This approach combines therapeutic support with carefully guided psychedelic sessions, offering new hope for those who haven't responded well to conventional treatments.
Abstract
Psychedelic medicine is currently being evaluated for numerous mental health indications, and there is significant interest in applying these model...
PAM trial protocol: a randomised feasibility study of psychedelic microdosing-assisted meaning-centred psychotherapy in advanced stage cancer patients.
Pilot and feasibility studies – February 12, 2024
Summary
New research explores an innovative approach to easing end-of-life distress in advanced cancer patients by combining meaning-centered psychotherapy with low-dose psychedelics. The protocol examines whether microdosing lysergic acid diethylamide (LSD) alongside therapy can help reduce anxiety and depression. This groundbreaking New Zealand study includes both indigenous and non-indigenous participants, marking a culturally inclusive approach to mental health care.
Abstract
An advanced cancer diagnosis can be associated with a significant profile of distress. Psychedelic compounds have shown clinically significant effe...
The Use of Psychedelics for Grief Following Death due to Advanced Illness: A Scoping Review.
Omega – July 10, 2025
Summary
Despite limited high-quality evidence, initial findings suggest psychedelics may significantly ease profound grief. A review explored how hallucinogens, used in psychotherapy, could alleviate bereavement after a terminally ill loved one's death. Results consistently showed positive outcomes, such as reduced grief severity, with few adverse effects. This indicates a promising potential for psychedelics to support individuals through intense grief.
Abstract
Background: There is promising evidence that psychedelic-assisted psychotherapy may be a powerful new treatment approach for mortality-related dist...
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Ochsner Journal – January 01, 2023
Summary
Psychedelics offer a promising new avenue for treating anxiety disorders. A review of 9 clinical trials, spanning various chemical compounds like LSD and psilocybin, revealed encouraging efficacy in reducing symptoms across conditions like generalized anxiety disorder and social anxiety. Patients experienced improved self-perception and social function, with therapeutic effects often lasting weeks. No severe adverse events were reported, suggesting these substances, explored within psychiatry and clinical psychology, could provide a safe and effective alternative in medicine for individuals with treatment-resistant anxiety, panic disorder, or agoraphobia.
Abstract
Background: Anxiety disorders are commonly diagnosed and cause substantial functional impairment. A mixture of pharmacologic and psychosocial treat...
People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences
Drugs Education Prevention and Policy – December 10, 2020
Summary
A single psychedelic experience, often involving psilocybin, may significantly reduce mental health symptoms stemming from racism. An internet survey of 313 Black, Indigenous, and people of color (BIPOC) revealed moderate reductions in traumatic stress (d=-.45), depression (d=-.52), and anxiety (d=-.53) in the 30 days post-use. This suggests a powerful role for hallucinogens in clinical psychology and psychiatry. Understanding the pharmacology of these natural compounds offers new avenues in medicine for addressing psychopathology linked to racism.
Abstract
This study examined how psychedelics reduced symptoms of racial trauma among black, indigenous, and people of color (BIPOC) subsequent to an experi...
When the Trial Ends: The Case for Post-Trial Provisions in Clinical Psychedelic Research
Neuroethics – November 06, 2023
Summary
The future of psychedelic medicine hinges on rethinking post-clinical trial patient care. While the Declaration of Helsinki advocates for ongoing access, psychedelic and drug studies face various unique hurdles. Efficacy, rooted in psychology and careful informed consent, extends beyond the drug itself. Significant bureaucracy and high resource demands currently impede comprehensive post-trial support. Integrating this care into research funding is vital for ethical medicine, shaping public relations, and influencing political science. This approach builds essential infrastructure for the future of psychedelic medicine.
Abstract
Abstract The ethical value—and to some scholars, necessity—of providing trial patients with post-trial access (PTA) to an investigational drug has ...
Treatment and therapy of mental health conditions in the Global South using psychedelics: A scoping review and narrative synthesis
Journal of Psychedelic Studies – June 21, 2024
Summary
Traditional plant medicines show renewed promise for mental health. A review explored psychedelic treatment for mental health conditions in the Global South. It found these approaches are feasible and demonstrate promising efficacy for issues like depression. Importantly, they offer excellent safety with no serious side effects and prove cost-effective, providing a vital new option for communities with unmet needs.
Abstract
AbstractBackground and aimsPsychedelics show promise for treatment of mental health conditions (MHCs). But there is relatively little research on i...
The influence of stakeholder interests on safety outcome reporting in psychedelic research and implications for science communication.
Trends in psychiatry and psychotherapy – January 01, 2025
Summary
No Summary
Abstract
Psychedelics are a group of psychoactive substances that produce complex and subjective changes to consciousness and carry unique safety considerat...
Mindfulness meditation and psychedelics: potential synergies and commonalities
Pharmacological Reports – November 06, 2023
Summary
Combining **mindfulness** **meditation** with **psychedelics** offers a powerful new **psychological intervention** for **mental health**. Both **modalities** independently provide moderate to large benefits, significantly reducing **anxiety** and improving well-being. Evidence suggests these psychedelic treatments and mindfulness practices share mechanisms, including altered self-consciousness and present-moment awareness, impacting **neurotransmitter receptor influence on behavior**. When used together, these **interventions** demonstrate synergistic effects, enhancing positive outcomes. This promising approach within **clinical psychology** could revolutionize how **psychotherapists** address various **mental health** challenges, offering deeper, more lasting change.
Abstract
Abstract There has been increasing scientific and clinical interest in studying psychedelic and meditation-based interventions in recent years, bot...
Mystical and Affective Aspects of Psychedelic Use in a Naturalistic Setting: A Linguistic Analysis of Online Experience Reports
Journal of Psychoactive Drugs – November 03, 2023
Summary
Mystical experiences frequently coexist with challenging elements during psychedelic journeys, according to an analysis of 7,317 online accounts. Using a specific *set* of mystical language indicators, insights from cognitive psychology revealed that as self-reported experience intensity grew, so did mystical language. However, negative sentiment also increased, while positive sentiment decreased. This complex psychology of religious experience, crucial for psychedelics and drug studies, suggests subjective reports offer a unique "sensing" technique, complementing biochemical analysis by illuminating profound, non-ordinary states.
Abstract
Analyzing online retrospective experience reports of psychedelic use can provide valuable insight into their acute subjective effects. Such reports...
The need for establishing best practices and gold standards in psychedelic medicine.
Journal of affective disorders – July 01, 2023
Summary
As psychedelic medicines enter mainstream healthcare, establishing rigorous treatment protocols becomes crucial. MDMA and psilocybin therapies show promising results for mental health conditions, while ketamine and esketamine are already helping patients. Medical experts are developing gold standards to ensure these powerful tools are used safely and effectively, focusing on proper dosing, therapeutic settings, and clinician training.
Abstract
Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and...
Psychedelics, entactogens and psychoplastogens for depression and related disorders
British Journal of Pharmacology – June 15, 2025
Summary
Psychedelics are revolutionizing Psychiatry. Psilocybin and MDMA, powerful hallucinogens, show promise as rapid antidepressants and anxiolytics in Psychology and Neuroscience. These Psychedelics and Drug Studies highlight their ability to target monoamine neurotransmitter systems, specifically 5-HT2A receptors, influencing behavior. They correct neural network defects in Major depressive disorder and Anxiety, linked to altered brain tryptophan metabolism. Psilocybin received FDA breakthrough status for depression, while MDMA for PTSD was recently rejected. This offers new hope for severe mental health conditions.
Abstract
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin...
Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans
Chronic Stress – August 12, 2020
Summary
Many Special Operations Forces Veterans reported profound improvements in mental health and cognition after a unique therapy. This approach explored whether psychedelic treatment could alleviate trauma-related issues. Researchers surveyed 51 Veterans who received ibogaine and 5-MeO-DMT. Participants reported significant reductions in PTSD, depression, anxiety, suicidal ideation, and cognitive impairment. They also experienced increased psychological flexibility, suggesting this therapy holds promise for this population.
Abstract
Background U.S. Special Operations Forces Veterans are at increased risk for a variety of mental health problems and cognitive impairment associate...
Psychedelic Identity Shift: A Critical Approach to Set And Setting
Kennedy Institute of Ethics journal – December 01, 2022
Summary
Psilocybin-assisted smoking cessation profoundly reshapes a person's **identity**, offering powerful **empowerment**. A **psychotherapist** using specific frameworks, or "set," alongside **psilocybin** can facilitate rapid shifts in self-perception, as shown in a pilot **smoking cessation** study. This **narrative** analysis from **Psychedelics and Drug Studies** highlights how structured support interacts with the substance. As **psychedelics** become **mainstream**, respecting patient **autonomy** and understanding this **psychology** of change is crucial for ethical practice.
Abstract
While the literature on psychedelic medicine emphasizes the importance of set and setting alongside the quality of subjective drug effects for ther...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics
Neurotrauma Reports – January 26, 2024
Summary
Many with spinal cord injuries are exploring psychedelics like psilocybin and LSD. A key insight reveals they often experience intense muscle spasms and other sensitivities, suggesting a unique, peripherally dominant serotonin-like reaction. Understanding this phenomenon is vital for developing protocols to safely harness the therapeutic potential of these compounds, including MDMA, for this population.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Adverse Events in Studies of Classic Psychedelics
JAMA Psychiatry – September 04, 2024
Summary
Healthy participants experienced zero serious adverse effects from classic hallucinogens like psilocybin. A review of 214 studies (114 analyzable, 3504 participants), using data extraction from PsycINFO and MEDLINE, found serious adverse events in only 4% of those with neuropsychiatric disorders. Nonserious adverse effects needing medicine were similarly rare. While generally well-tolerated in clinical psychology and psychiatry, understanding these psychedelics' neurotransmitter receptor influence on behavior is vital for new populations in drug studies, especially for compounds from chemical synthesis and alkaloids.
Abstract
Importance A clear and comprehensive understanding of risks associated with psychedelic-assisted therapy is necessary as investigators extend its a...
Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies
Frontiers in Psychology – June 06, 2025
Summary
Psychedelics profoundly enhance existential meaning, a vital aspect of psychology, across diverse contexts including a clinical trial for depression, a healthy volunteer study, and naturalistic retreats. Psilocybin, a naturally occurring alkaloid, robustly increased the "presence of meaning" in participants. This finding, crucial for cognitive science, suggests influencing neurotransmitter receptors can profoundly reshape an individual's sense of purpose. Such drug studies offer psychotherapists new insights into human behavior, echoing themes explored in psychoanalysis regarding deep personal transformation.
Abstract
Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carr...
The forgotten psychedelic: Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
OpenAlex – October 22, 2024
Summary
The hallucinogen 2C-B shows unique promise in psychology, potentially offering advantages over psilocybin. In 22 healthy volunteers, administration of 20 mg 2C-B, 15 mg psilocybin, or placebo was explored via 7T fMRI. Both psychedelics increased brain complexity and between-network connectivity. Crucially, 2C-B exhibited less pronounced reductions in certain brain connections but elevated others, reflecting distinct neuropharmacological profiles. These insights are vital for neuroscience and cognitive psychology, guiding future drug studies and potential new pharmacotherapies.
Abstract
As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored f...
Psychedelics and Other Psychoplastogens for Treating Mental Illness
Frontiers in Psychiatry – October 04, 2021
Summary
Psychedelics offer remarkable hope in Medicine, demonstrating sustained therapeutic effects for mental illness, including Anxiety and depression, often after a single dose. These compounds, stemming from chemical synthesis, influence brain chemistry via neurotransmitter receptors, effectively rewiring brain circuits. In Psychiatry, they are among the most effective chemical modulators of neural plasticity identified through drug studies. This Neuroscience-backed approach marks a paradigm shift for Psychology, moving beyond symptom management toward potentially curing underlying pathophysiology. Future efforts aim to develop non-hallucinogenic versions for broader use by psychotherapists.
Abstract
Psychedelics have inspired new hope for treating brain disorders, as they seem to be unlike any treatments currently available. Not only do they pr...
Med Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedelics, and Lumryz
Psychiatric News – July 27, 2023
Summary
The FDA is fast-tracking an anti-amyloid beta vaccine for Alzheimer's disease, with early clinical trial data showing an antibody response by week 6. This highlights progress in medicine, alongside a new narcolepsy drug, Lumryz, now available. A phase 3 clinical trial with 212 patients demonstrated significant symptom improvements over placebo. Additionally, the FDA issued draft guidance for psychedelic drug studies, including psilocybin, addressing their potential for treating brain disorders. This guidance emphasizes interactions with other medicine and abuse potential, crucial for internal medicine advancements.
Abstract
Back to table of contents Previous article Next article Med CheckFull AccessMed Check: FDA, Anti-Amyloid Beta Vaccine, Clinical Trials of Psychedel...
In naturalistic psychedelic use, group use is common and acceptable
Journal of Psychedelic Studies – June 19, 2023
Summary
Subjective negative mental health outcomes from psychedelic use are rare and not linked to solo or group modalities, according to naturalistic observation. While solo use was reportedly more common for mental health goals, natural compound pharmacology studies indicate no difference in overall mental health benefit between solo and group settings. A vast majority (95% solo, 91% group) of these experiences occur informally. This challenges clinical psychology’s traditional focus, suggesting group approaches in medicine for mental health could be equally safe and beneficial, effectively minimizing harm.
Abstract
Abstract Background and aims Most modern modalities of psychedelic-assisted psychotherapy (PAP) aim to minimize harm and maximize support by utiliz...
Authenticity and Love Drugs: Insights from Psychedelic Therapy.
AJOB neuroscience – June 16, 2025
Summary
Many view "love drugs" as unethical because the emotions they create are seen as inauthentic. However, new perspectives, drawing from psychedelic-assisted therapy, suggest that psychoactive drugs can indeed foster genuine, meaningful feelings. If these experiences lead to lasting positive change and and align with personal desires, our ethics around authenticity may need rethinking, embracing the potential for profound therapy.
Abstract
In "Prescription for Love: An Experimental Investigation of Laypeople's Relative Moral Disapproval of Love Drugs," Lantian, Boudesseul, and Cova (2...
Chemoenzymatic Synthesis of 5-Methylpsilocybin: A Tryptamine with Potential Psychedelic Activity
Journal of Natural Products – March 05, 2021
Summary
A novel psilocybin analogue, 5-methylpsilocybin, exhibits potent biological activity. Its chemical synthesis involved a unique *in vitro* enzymatic phosphorylation of a tryptamine derivative, 5-methylpsilocin, utilizing a *Psilocybe cubensis* kinase. Biochemical analysis ensured high purity of this new hallucinogen. In drug studies, it showed psychedelic-like effects in mice, proving more potent than dimethyltryptamine but less potent than psilocybin. This innovative chemistry expands the realm of synthetic alkaloids.
Abstract
A novel analogue of psilocybin was produced by hybrid chemoenzymatic synthesis in sufficient quantity to enable bioassay. Utilizing purified 4-hydr...
The Epidemiology of Psychedelic Use Among United States Military Veterans
Journal of Psychoactive Drugs – September 12, 2024
Summary
A striking 51% of 426 US military veterans reported using psychedelics, largely for healing (70%) or spiritual purposes (48%). Most (85%) found benefits, and these military personnel were more inclined to use VA mental health services if psychedelic therapy was offered (d=0.64; d=0.79). However, 59% experienced adverse outcomes. Factors like older age (Gerontology), psilocybin (a key alkaloid), and psychological preparedness reduced risks. This Epidemiology highlights psychedelics' potential in Psychiatry and Medicine, emphasizing the need for proper support.
Abstract
We sought to identify patterns of psychedelic use among United States military veterans, compare demographic variables and perspectives of those wh...
Neural mechanisms of psychedelic visual imagery.
Molecular psychiatry – April 01, 2025
Summary
Brain scans reveal how psychedelic mushrooms create vivid mental imagery. When people see colorful visions with closed eyes during a psilocybin experience, it's because the brain's visual areas become more self-regulating while allowing stronger feedback from higher brain regions. This unique pattern helps explain the rich visual experiences commonly reported during psychedelic states.
Abstract
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agon...
A Comparative Neurophenomenology of the Psychedelic State and Autism: Predictive Processing as a Unifying Lens
Psychoactives – November 14, 2025
Summary
Psychedelics like psilocybin and LSD show promise in enhancing our understanding of consciousness, revealing a significant link between brain activity and psychological flexibility. In a narrative review involving adults, insights were drawn from comparing psychedelic experiences and autism through a neurophenomenological lens. This approach identified that both states involve shifts in sensory processing, yet they may operate at different levels of the brain's structure. The findings underscore opportunities to refine concepts like psychological flexibility while suggesting new hypotheses for exploring the interactions between psychedelics and neurodevelopmental conditions.
Abstract
Serotonergic psychedelics, particularly psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT), are increasingly recognised as ...
Psychedelics, spirituality, and existential distress in patients at the end of life.
Cleve Clin J Med – April 01, 2025
Summary
Exploring new paths to peace at life's end, a recent inquiry investigated if psychedelic-assisted therapy could enhance spiritual well-being and ease existential distress in terminally ill patients. Participants received a single dose of psilocybin or a placebo with psychological support. Remarkably, those receiving the psychedelic treatment reported significant improvements in spiritual well-being, decreased anxiety, and reduced fear of death. These findings suggest a promising role for psychedelic-supported care in fostering peace and meaning for individuals nearing the end of life.
Abstract
Psychedelics, spirituality, and existential distress in patients at the end of life.
Disability rights and experiential use of psychedelics in clinical research and practice.
Npj mental health research – July 02, 2024
Summary
No Summary
Abstract
Given the renewed interest in the use of psychedelics for the treatment of mental and substance use disorders in recent decades, there has also bee...
Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses.
Neuroscience and biobehavioral reviews – July 01, 2022
Summary
No Summary
Abstract
Clinical research into serotonergic psychedelics is expanding rapidly, showing promising efficacy across myriad disorders. Resting-state functional...
Data Sheet 1_Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.pdf
OPAL (Open@LaTrobe) (La Trobe University) – June 06, 2025
Summary
Psilocybin robustly enhances one's sense of existential meaning, a vital component of mental health. Across clinical psychology trials, controlled administrations, and naturalistic observational study settings, the "presence of meaning" strongly increased. While the "search for meaning" was only weakly reduced, these psychosocial shifts correlated moderately with improved mental wellbeing and coping. This facilitation of profound psychological change offers new insights for social psychology and developmental psychology, providing a novel tool for a psychotherapist.
Abstract
Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carr...
Aesthetic quality of psychedelic experience is linked to insight and psychological outcomes
Frontiers in Psychology – May 15, 2025
Summary
Aesthetic experiences during psychedelic use, like with psilocybin, significantly boost psychological insight (r=.48) and emotional breakthrough (r=.40). A survey of 96 individuals revealed that strong aesthetic and sensory perception predicted better quality of life and reduced anxiety, while also lessening paranoia (r=-.36). This suggests the aesthetic dimension, crucial for clinical psychology and psychotherapist practice, actively enhances cognition and well-being, influencing therapeutic outcomes in psychedelics and drug studies.
Abstract
Introduction The aesthetic qualities of psychedelic experiences have long been documented, but their specific contribution to therapeutic outcomes ...
Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review.
Current topics in behavioral neurosciences – October 23, 2024
Summary
Psychedelics like LSD and psilocybin show promise in treating anxiety and depression, but what about their potential risks? Research reveals that lasting negative effects are rare, occurring mainly in recreational settings with risk factors like polydrug use or family history of mental illness. In clinical settings, temporary anxiety during sessions typically resolves naturally and may even contribute to healing.
Abstract
There is a large and rapidly growing body of literature investigating the therapeutic effects of classic psychedelics in affective and anxiety diso...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.
Neurotrauma reports – January 01, 2023
Summary
People with spinal cord injuries experience unique reactions to psychedelics like psilocybin and LSD, marked by intense muscle spasms and sweating. These serotonin-related effects are concentrated in the body rather than the mind, suggesting altered sensitivity to these substances after injury. While patients return to baseline, these physical responses can diminish the therapeutic benefits.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Psychedelic integration and transformation
Consciousness, Spirituality & Transpersonal Psychology – December 22, 2023
Summary
Beyond the trip itself, psychedelic experiences can lead to lasting positive changes when properly integrated into daily life. Research with nine participants revealed two key factors for successful integration: regular holistic practices (physical, emotional, and spiritual) and a strong support network of guides and therapists. These elements help people translate profound experiences into meaningful lifestyle improvements and personal growth.
Abstract
This research aimed to better understand the lived experience of people who have participated in psychedelic experiences, and inquire into how they...
Intravenous Administration of Serotonergic Psychedelics Produce Short-lasting Changes in Sleep-Wake Behavior and High Gamma Functional Connectivity in Rats
OpenAlex – October 14, 2025
Summary
Psychedelics minimally impact sleep, yet profoundly alter brain activity. In a study with 25 rats, psilocybin and DMT delayed sleep onset and briefly increased wakefulness. These Psychedelics and Drug Studies highlight Neurotransmitter Receptor Influence on Behavior, showing psilocybin enhanced high gamma brain connectivity during wakefulness and sleep. While this research focuses on serotonin, other drug studies, like a Nicotinic Acetylcholine Receptors Study, explore diverse neural systems to understand drug effects.
Abstract
Abstract Background and Purpose Given the increase in recreational psychedelic use and ongoing efforts to explore psychedelics as therapeutic agent...
Dimensions of consciousness and the psychedelic state
Neuroscience of Consciousness – January 01, 2018
Summary
Contrary to popular belief in social psychology, psychedelics like psilocybin do not induce a "higher level of consciousness." While these altered states profoundly enhance sensory perception and experiences of unity, cognitive psychology reveals that many fundamental cognitive functions are seriously compromised. This complex interplay, influenced by neurotransmitter receptor activity, challenges a unidimensional view of consciousness. Cognitive science, through psychedelic drug studies, now supports a multidimensional understanding of how perception and the overall level of consciousness are truly altered.
Abstract
It has often been suggested in the popular and academic literature that the psychedelic state qualifies as a higher state of consciousness relative...
Neural mechanisms of psychedelic visual imagery
OpenAlex – September 09, 2022
Summary
Psilocybin, a potent hallucinogen, profoundly alters visual perception. Using functional magnetic resonance imaging (fMRI) on 24 adults, Neuroscience and Psychology investigations reveal how this psychedelic drug impacts the visual cortex. Under psilocybin, enhanced top-down feedback from higher visual areas to the early visual cortex appears to drive vivid, eyes-closed visual imagery. This suggests psilocybin reduces external stimulus impact, allowing internal cognitive processes to dominate perception. These insights from Psychedelics and Drug Studies advance our understanding of visual perception and the brain's mechanisms for creating internal visual experiences.
Abstract
Abstract Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence sugg...
Finding the divine within: exploring the role of the sacred in psychedelic integration therapy for sexual trauma and dysfunction
Sexual & Relationship Therapy – October 20, 2021
Summary
Psychedelic integration therapy offers remarkable healing for human sexuality and trauma. Guided by a psychotherapist, individuals using natural compounds like psilocybin report profound embodied pleasure, liberated from shame. This psychological approach fosters a healthy identity and increased sexual satisfaction, addressing deep-seated issues that can underpin addiction. Clients describe direct, existential meaning through divine connection, facilitating sustained well-being. This innovative area within psychedelics and drug studies holds significant promise.
Abstract
During the last two decades, psychedelic-assisted therapy has emerged as one of the most promising novel treatments for depression, anxiety, PTSD, ...
Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting
BMJ Open – September 01, 2017
Summary
Lifetime psychedelic drug use was associated with a 60% reduced hazard for new suicidality among 290 marginalized women in a 54-month longitudinal cohort study. Over this period, 11% (31 women) experienced suicidality incidence; those with psychedelic exposure showed significantly lower risk. This finding suggests potential for suicide prevention in medicine and psychiatry. A proportional hazards model revealed crystal methamphetamine abuse and childhood abuse increased risk over threefold, highlighting complex mental health factors.
Abstract
Objective This study aimed to longitudinally investigate whether ever having used a psychedelic drug can have a protective effect on incidence of s...
Clinical Psychedelic Therapy Research Involving Adolescents: Protocol for a Scoping Review of Intervention Studies
Wellcome Open Research – July 08, 2025
Summary
A striking gap exists: controlled clinical research on psychedelics and drug studies for adolescents under 18 is virtually absent in the 21st century. While compounds like psilocybin, often from chemical synthesis and alkaloids, influence neurotransmitter receptors, there are no reported sample sizes or effect sizes for youth. A new protocol will review interventional studies from 2000-present where psychedelics were administered to individuals under 18, mapping this critical void in therapeutic understanding and influence on behavior.
Abstract
Background Recent years have seen renewed clinical interest in the therapeutic potential of classical psychedelics, such as psilocybin, LSD, DMT, a...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...
Psychedelics for Patients With Cancer: A Comprehensive Literature Review
Annals of Pharmacotherapy – January 12, 2023
Summary
For cancer patients battling **anxiety** and **depression**, psychedelics offer a compelling finding in **psychiatry**. Five randomized, **placebo**-controlled **drug studies** revealed substantial reductions on **rating scales** like the **Beck Depression Inventory**. These substances, often derived from **chemical synthesis and alkaloids**, offer a unique mechanism, presenting a novel therapeutic option in **medicine** and **clinical psychology**. Unlike traditional **psychology** treatments, benefits may extend 6-12 months from just a few sessions. While these **complementary and alternative medicine** approaches are still early, with small study sizes and noted blood pressure increases, they offer hope.
Abstract
Objective: To assess the role of psychedelics in the treatment of anxiety or depression among patients with cancer. Data Sources: PubMed search fro...
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Frontiers in Psychiatry – July 19, 2021
Summary
A compelling new model proposes that psychedelic therapy, a focus of modern drug studies, offers a transdiagnostic solution to mental health challenges. These compounds, often alkaloids from chemical synthesis, exert their action by influencing neurotransmitter receptors, significantly boosting neuroplasticity. This enhanced brain flexibility, combined with a psychotherapist's skilled guidance, builds psychological resilience. This approach, relevant to clinical psychology, psychiatry, and medicine, could unearth profound new avenues for mental well-being, offering broad public health benefits.
Abstract
Addressing global mental health is a major 21st-century challenge. Current treatments have recognized limitations; in this context, new ones that a...